The management of patients with advanced non-small cell lung cancer (NSCLC), who do not have a targetable driver mutation has come a long way in the past few years, since the advent of immune checkpoint inhibitors. Gone are the days when we used to pick one platinum agent, combine it with a non-platinum agent and hope that the patient in question was one of the lucky 20% to have a response. The KEYNOTE-024 study demonstrated the superiority of pembrolizumab alone in patients with high PD-L1 expression (Tumor Proportion Score (TPS) ≥50%) (22C3 antibody) (1). The KEYNOTE-189 and KEYNOTE-407 studies showed the superiority of pembrolizumab in combination with a platinum-based doublet chemotherapy compared to chemotherapy alone in non-squamous NSCLC and squamous cell lung cancer, respectively, with any level of PD-L1 expression (2,3). Similarly, the IMpower 150 study that evaluated carboplatin-paclitaxel-bevacizumab +/- atezolizumab in patients with advanced non-squamous NSCLC found that, similar to KEYNOTE-189, patients who received atezolizumab had a better median overall survival compared to chemotherapy alone (4). Based on these trials, patients who had a high PD-L1 expression receive pembrolizumab alone, while patients with NSCLC with lower expression can receive either pembrolizumab or atezolizumab along with the histology-appropriate, platinum-based chemotherapy.

The results of KEYNOTE-042 should be examined in this context. KEYNOTE-042 was a randomized, open-label, global phase 3 study in adults with treatment naïve, locally advanced or metastatic NSCLC without a sensitizing EGFR mutation or ALK translocation, and a good performance status (ECOG 0–1) and a PD-L1 TPS of 1% or greater (5). Enrolled patients were randomly assigned to receive pembrolizumab, or investigator’s choice of platinum-based chemotherapy for four to six cycles. Overall survival was significantly longer in the pembrolizumab group than in the chemotherapy group in all three TPS populations analyzed. The hazard ratios for survival in the ≥50%, ≥20% and the ≥1% cohorts were 0.69, (95% CI, 0.56–0.85); 0.77, (95% CI, 0.64–0.92) and 0.81 (95% CI, 0.71–0.93) respectively, favoring pembrolizumab. The median survival in these cohorts for pembrolizumab and chemotherapy were 20.0 vs. 12.2 months, 17.7 vs. 13.0 months, and 16.7 vs. 12.1 months, respectively. Consistent with previous studies, the adverse event profile was better in the pembrolizumab group. There were no new safety signals identified in this study.

These results are in contrast to those seen in the CheckMate 026 trial, that looked at nivolumab in a similar setting (6). In this study, there was no improvement in either progression free survival or overall survival with nivolumab compared to platinum-based chemotherapy in patients with a PD-L1 level (Dako 28–8 antibody) of ≥1%. To add another twist to this story, the recently published results of the CheckMate 227 trial showed that a combination of nivolumab and the CTLA-4 inhibitor, ipilimumab, resulted in a longer overall survival than chemotherapy, independent of the level of PD-L1 expression, as measured by the Dako 28–8 assay (7). Similar to the KEYNOTE-042 study, patients with PD-L1 expression of ≥1% had a median
overall survival of 17.1 months with the combination immunotherapy, compared to 14.9 months with platinum based chemotherapy. In this study, patients who were treated with nivolumab alone had a median survival of 15.7 months that was similar to the combination of nivolumab and ipilimumab (hazard ratio for the combination 0.90; 95% CI, 0.76–1.07). More intriguingly, in patients with a PD-L1 expression of <1%, the combination immunotherapy arm had a median overall survival of 17.2 months compared to 12.2 months with chemotherapy. It is unlikely that these discrepancies in the KEYNOTE-042 and the CheckMate 026 and 227 trials are a related to a difference in the methodology used to test for PD-L1 as the 2 assays used namely, 22 C3 and 28–8 have been shown to be concordant in previous studies (8).

These results raise the important question about the role of cytotoxic chemotherapy in patients whose tumors have a PD-L1 TPS of ≥1%. While the KEYNOTE-042 studied three different cohorts of patients with PD-L1 TPS of ≥1%, ≥20% and ≥50%, unfortunately they did not report the results of patients with TPS ≥1–49% separately. Given the increasing hazard ratios with inclusion of lower levels of PD-L1 expression in the analysis, it is likely that the majority of the benefit seen in the ≥1% and ≥20% cohorts was driven by the benefit in patients with TPS ≥50%. If this is true, then patients with PD-L1 expression of 1–49% should receive chemoimmunotherapy rather than immunotherapy alone. Thus, results of the KEYNOTE-189, IMPower150 and KEYNOTE-407 studies should guide the management of these patients, who should then be offered a platinum doublet in combination with pembrolizumab. The other option would be to use the results of the CheckMate 227 study and treat these patients regardless of PD-L1 expression with a combination of nivolumab and ipilimumab.

Based on the results of the KEYNOTE-042 study, it would be tempting to treat patients were unlikely to tolerate cytotoxic chemotherapy with pembrolizumab alone. However, it must be noted that this study did not include patients with a performance status of ECOG-2 and was limited to good performance status patients. Prior studies in PS2 patients have shown that lung cancer patients with a poor performance status, irrespective of age, have an increased incidence of adverse effects with standard chemotherapy and have a poorer overall survival (9,10). Outcomes data with platinum based combination chemotherapy suggest that while the doublet therapy provided superior outcomes compared to monotherapy, these were inferior to those seen in good performance status patients. It is noteworthy that this improvement in survival was at the cost of greater toxicity (9,11,12). If this argument is extended to the current context, it is likely that these patients will tolerate pembrolizumab better and therefore reap the benefits of this drug as well.

In conclusion, the results of the KEYNOTE-042 trial provide another option for the management of patients with advanced NSCLC. However, it is still unclear if patients with low PD-L1 expression have an added benefit from cytotoxic chemotherapy. Our proposed approach would be to use a combination of platinum doublet with pembrolizumab or a combination of nivolumab and ipilimumab in patients who are felt to be able to tolerate these agents. In patients who are not candidates for cytotoxic chemotherapy, options would include a combination of nivolumab and ipilimumab or single agent pembrolizumab, although it would be good to have data specific to these patients. The results of ongoing studies should help answer some of these questions.

Acknowledgments
None.

Footnote

Conflicts of Interest: LN Buddharaju—Advisory Board: Novartis. AK Ganti—Consultant: AstraZeneca, Roche; Research support: Takeda, Merck, Apexigen, Novartis, BMS; Advisory Board: AstraZeneca.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References


Cite this article as: Buddharaju LN, Ganti AK. Immunotherapy in lung cancer: the chemotherapy conundrum. Chin Clin Oncol 2020. doi: 10.21037/cco.2020.01.05